Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,937.50 | 41.90 | -0.47% |
CAC 40 | 7,818.28 | 32.15 | -0.41% |
DAX 40 | 24,295.93 | 55.11 | 0.23% |
Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
FTSE 100 | 9,138.37 | 76.88 | 0.85% |
HKSE | 25,383.07 | 284.11 | -1.11% |
NASDAQ | 21,057.96 | 37.94 | 0.18% |
Nikkei 225 | 41,450.36 | 375.98 | -0.90% |
NZX 50 Index | 12,855.10 | 49.97 | 0.39% |
S&P 500 | 6,363.35 | 4.44 | 0.07% |
S&P/ASX 200 | 8,670.10 | 39.30 | -0.45% |
SSE Composite Index | 3,593.38 | 12.35 | -0.34% |